title: Therapies: Drugs, Scopes and Transjugular Intrahepatic Portosystemic Shunt--When and How?
abstract: Variceal bleeding is the most serious complication of portal hypertension. All cirrhotic patients should be screened endoscopically for varices which are present in about 30% of compensated and 60% of decompensated patients at diagnosis. In patients without varices, endoscopy surveillance should be continued every 2 years. Patients with high-risk varices (moderate or large in size, or with red color signs, or in Child-Pugh C patients) should be treated with a nonselective β-blocker to prevent bleeding (propranolol, nadolol or carvedilol). Endoscopic banding ligation is also effective for the prevention of first bleeding, and it is the first choice in patients with contraindications or intolerance to β-blockers. Acute variceal hemorrhage still has a high mortality rate (around 15%) and requires intensive care management and conservative blood transfusion policy. Treatment is based on the combined use of vasoactive drugs, endoscopic band ligation and prophylactic antibiotics. Failures are best managed by transjugular intrahepatic portosystemic shunt (TIPS). Balloon tamponade or specifically designed covered esophageal stents can be used as a bridge to definitive therapy in unstable patients. Early, preemptive TIPS might be the first choice in patients at high risk of failure (Child-Pugh B with active bleeding or Child-Pugh C up to 13 points). Patients surviving a variceal bleeding are at high risk of rebleeding. A combination of β-blockers and endoscopic band ligation is the most effective therapeutic approach. Preliminary data suggest that the addition of simvastatin increases survival in these patients.
authors.affiliation: University of Alberta, Edmonton, Alta., Canada.
authors.forename: Juan G
authors.initials: JG
authors.lastname: Abraldes
authors.forename: Puneeta
authors.initials: P
authors.lastname: Tandon
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D021721:Balloon Occlusion; D003131:Combined Modality Therapy; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000517:prevention & control*; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006975:Hypertension, Portal / Q000209:etiology / Q000628:therapy*; D008026:Ligation; D008103:Liver Cirrhosis / Q000150:complications*; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D019821:Simvastatin / Q000627:therapeutic use; D015607:Stents
chemical_list: D000319:Adrenergic beta-Antagonists; D000924:Anticholesteremic Agents; D019821:Simvastatin